Resistance mutations to BTK inhibitors originate from the NF-κB but not from the PI3K-RAS-MAPK arm of the B cell receptor signaling pathway
Since the first clinical report in 2013, inhibitors of the intracellular kinase BTK (BTKi) have
profoundly altered the treatment paradigm of B cell malignancies, replacing chemotherapy …
profoundly altered the treatment paradigm of B cell malignancies, replacing chemotherapy …
Therapeutic options for relapsed/refractory mantle cell lymphoma
Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma in which
immunochemotherapy, with or without high-dose therapy, and autologous stem cell …
immunochemotherapy, with or without high-dose therapy, and autologous stem cell …
Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma
Mantle cell lymphoma (MCL) is a lethal hematological malignancy with a median survival of
4 years. Its lethality is mainly attributed to a limited understanding of clinical tumor …
4 years. Its lethality is mainly attributed to a limited understanding of clinical tumor …
Blockade of CCR1 induces a phenotypic shift in macrophages and triggers a favorable antilymphoma activity
Tumor-associated macrophages (TAMs) within the tumor microenvironment (TME) play an
important role in tumor growth and progression. TAMs have been involved in producing …
important role in tumor growth and progression. TAMs have been involved in producing …
The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma
HC Lantermans, F Ma, A Kuil, S van Kesteren… - Leukemia, 2024 - nature.com
Although Bruton's tyrosine kinase (BTK) inhibitors (BTKi) have significantly improved patient
prognosis, mantle cell lymphoma (MCL) is still considered incurable due to primary and …
prognosis, mantle cell lymphoma (MCL) is still considered incurable due to primary and …
A gentle introduction to understanding preclinical data for cancer pharmaco-omic modeling
C Piyawajanusorn, LC Nguyen, G Ghislat… - Briefings in …, 2021 - academic.oup.com
A central goal of precision oncology is to administer an optimal drug treatment to each
cancer patient. A common preclinical approach to tackle this problem has been to …
cancer patient. A common preclinical approach to tackle this problem has been to …
Multifaceted regulation of enhancers in cancer
Q Xiao, Y Xiao, LY Li, MK Chen, M Wu - Biochimica et Biophysica Acta …, 2022 - Elsevier
Enhancer is one kind of cis-elements regulating gene transcription, whose activity is tightly
controlled by epigenetic enzymes and histone modifications. Active enhancers are classified …
controlled by epigenetic enzymes and histone modifications. Active enhancers are classified …
Kinome-Wide Virtual Screening by Multi-Task Deep Learning
Deep learning is a machine learning technique to model high-level abstractions in data by
utilizing a graph composed of multiple processing layers that experience various linear and …
utilizing a graph composed of multiple processing layers that experience various linear and …
Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma
Despite the remarkable success of targeted therapies for mantle cell lymphoma (MCL),
including inhibitors of Bruton tyrosine kinase (BTK) and CD19-directed chimeric antigen …
including inhibitors of Bruton tyrosine kinase (BTK) and CD19-directed chimeric antigen …
A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas
JY Jang, I Hwang, H Pan, J Yao… - The Journal of …, 2022 - Am Soc Clin Investig
Targeting lineage-defined transcriptional dependencies has emerged as an effective
therapeutic strategy in cancer treatment. Through screening for molecular vulnerabilities of …
therapeutic strategy in cancer treatment. Through screening for molecular vulnerabilities of …